Last reviewed · How we verify
High dose rhCC10
High dose rhCC10 is a recombinant human tracheobronchial antimicrobial peptide that has antimicrobial properties.
High dose rhCC10 is a recombinant human tracheobronchial antimicrobial peptide that has antimicrobial properties. Used for Treatment of respiratory infections.
At a glance
| Generic name | High dose rhCC10 |
|---|---|
| Sponsor | Tufts Medical Center |
| Drug class | Antimicrobial peptide |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
rhCC10 works by directly killing or inhibiting the growth of various pathogens, thereby reducing the severity of respiratory infections. Its mechanism of action is not fully understood, but it is thought to involve the disruption of microbial membranes and the inhibition of microbial enzymes.
Approved indications
- Treatment of respiratory infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome (PHASE2)
- Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose rhCC10 CI brief — competitive landscape report
- High dose rhCC10 updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI